Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab Biosimilar (QurCan Therapeutics Inc.), 曲妥珠单抗生物类似药(QurCan Therapeutics Inc.) |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization QurCan Therapeutics Inc.Startup |
Active Organization QurCan Therapeutics Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain metastases | Preclinical | CA | QurCan Therapeutics Inc.Startup | 07 Oct 2022 |